Back to search

Peptide record

TPDB42629

5-2C Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB42629
5-2C
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation N-terminal: Acetylation
Sequence
Ac-NYPQRPCRGDKGPDC-NH2
Physicochemical Analysis
C69H108N24O23S2
AEHILMFSTWV
P
1705.88
8.28
3
2
1
+1
6.02
-1.920
0.00
Mammalian: 1.4 hour Yeast: 3 min E.coli: >10 hour
1615
94.67
5
Residue Composition
number
0
A
2
R
1
N
2
D
2
C
0
E
1
Q
2
G
0
H
0
I
0
L
1
K
0
M
0
F
3
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 0 R: 2 N: 1 D: 2 C: 2 E: 0 Q: 1 G: 2 H: 0 I: 0 L: 0 K: 1 M: 0 F: 0 P: 3 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
15
C69H108N24O23S2
1705.88
8.28
+1
6.02
-1.920
Amidation
L
Linear
Acetylation
Antimicrobial
Synthetic
Evidence Records 12 records
Evidence 1 Activity

Activity

IC50
IC50 = 0.781 µM
Anticancer
0.781 µM

Target

Glioblastoma
U343
Brain

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 0.8717 µM
Anticancer
0.8717 µM

Target

Glioblastoma
U373MG
Brain

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 3 Activity

Activity

IC50
IC50 = 0.7607 µM
Anticancer
0.7607 µM

Target

Glioblastoma
U251
Brain

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 4 Activity

Activity

IC50
IC50 = 0.9164 µM
Anticancer
0.9164 µM

Target

Glioblastoma
U87-MG
Brain

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 5 Activity

Activity

IC50
IC50 = 3.064 µM
Anticancer
3.064 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 6 Activity

Activity

IC50
IC50 = 0.7847 µM
Anticancer
0.7847 µM

Target

Liver Cancer
Hep3B
Liver

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 7 Activity

Activity

IC50
IC50 = 1.107 µM
Anticancer
1.107 µM

Target

Renal Cancer
293T
Renal

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 8 Activity

Activity

IC50
IC50 = 9.74 µM
Anticancer
9.74 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 9 Activity

Activity

IC50
IC50 = 0.8061 µM
Anticancer
0.8061 µM

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 10 Activity

Activity

IC50
IC50 = 1.111 µM
Anticancer
1.111 µM

Target

Blood Cancer
HL-60
Blood

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 11 Activity

Activity

IC50
IC50 = 1.103 µM
Anticancer
1.103 µM

Target

Blood Cancer
K-562
Blood

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1
Evidence 12 Activity

Activity

IC50
IC50 = 1.055 µM
Anticancer
1.055 µM

Target

Blood Cancer
Hel
Blood

Assay & Model

MTT assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2016
EP3279210 B1